Slide 1: Investor Presentation October 30, 2025
Investor Presentation October 30, 2025 For Investor Relations Purposes Only Exhibit 99.3
Slide 2: Important Cautionary Statement Regarding Forward-looking Statements
Important Cautionary Statement Regarding Forward-looking Statements 2 INVESTOR PRESENTATION | October 2025 This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: the Company’s financial
Slide 3: Founded to Help Address the Opioid Crisis
Founded to Help Address the Opioid Crisis 1 Laffont CM, et al. Front Pharmacol. 2022;13:105213. doi:10.3389/fphar.2022.105213. 2 Nasser AF, et al. Clin Pharmacokinet. 2014;53(9):813-824. doi:10.1007/s40262-014-0155-0. 3 Jones AK, et al. Clin Pharmacokinet. 2021;60(4):527- 540. doi:10.1007/s40262- 02
Slide 4: Track Record of Strong Net Revenue Growth
1 Financial data provided by Indivior in its Annual Reports on Forms 20-F and 10-K filed with the SEC on June 5, 2023, March 6, 2024 and February 3, 2025. 2 Based on the midpoint of 2025 financial guidance ranges. 3 Other includes Sublingual Film/Tablets, OPVEE® & PERSERIS®. Track Record of Strong N
Slide 5: Clear Path to Generating Meaningful Cash Flows from Operations
Leverage Cost Structure… 1 Based on the midpoint of 2025 financial guidance ranges. 2 Non-GAAP operating expenses and adjusted EBITDA are Non-GAAP financial measures; see appendix for reconciliation. GAAP Net Income/(loss) of ($148m) in FY 2020, $205m in FY 2021, ($42m) in FY 2022, ($126m) in FY 202
Slide 6: Indivior Action Agenda
Indivior Action Agenda 6 Phase I – Generate Momentum – Underway I II III Grow U.S. SUBLOCADE net revenue Simplify the organization and establish “go-forward” operating model Determine actions and investments necessary to expand LAI penetration in U.S. BMAT category to accelerate U.S. SUBLOCADE net r
Slide 7: Progress on Phase I of the Indivior Action Agenda
Progress on Phase I of the Indivior Action Agenda 7 Grow SUBLOCADE in the U.S. LSE: London Stock Exchange. DTC: Direct-to-consumer. Simplify the organization and establish “go-forward” operating model Determine actions and investments necessary to expand LAI penetration in U.S. BMAT category to acce
Slide 8: SUBLOCADE
SZ iNDIVIOR SUBLOCADE*
Slide 9: Bipartisan Commitment to Addressing Opioid Crisis in the U.S.
c c c c Bipartisan Commitment to Addressing Opioid Crisis in the U.S. 9 U.S. Illicit Opioid Use Could Be 20 Times Higher Than Previously Estimated May 12, 2025 The SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R. 2483) reauthorizes key public health programs focused on preventi
Slide 10: ASAM BMAT Guidelines for Individuals Using High-Potency Synthetic Opioids
American Society of Addiction Medicine (ASAM) BMAT Guidelines For Individuals using High-Potency Synthetic Opioids (HPSO) Expert consensus based on limited available evidence suggests that the high plasma buprenorphine concentrations at steady state and continuous exposure offered by extended-releas
Slide 11: LAI Buprenorphine Medications are Under-Penetrated in the Treatment of OUD
12023 NSDUH Annual National Report (SAMSHA). 2Symphony and Indivior analytics, patient treated over the last twelve months. 3HCP Survey conducted Q3 2024. N=400 HCP and patients combined in qual and quant. LAI Buprenorphine Medications are Under-Penetrated in the Treatment of OUD 11 Current ~8% LAI
Slide 12: ≥2 ng/mL Buprenorphine Blood Plasma Levels Were Needed to Help Protect from Opioid-Rewarding Effects
Buprenorphine plasma concentrations >2 ng/mL ≥70% brain μORs are occupied less μORs are available for illicit opioids Low buprenorphine plasma concentrations few brain μORs are occupied more μORs are available for illicit opioids As buprenorphine plasma levels increase, the number of receptors avail
Slide 13: Mean Buprenorphine Levels During Induction, Dose-Stabilization, and First 2 Injections
Mean Buprenorphine Levels During TM BUP* Induction, Dose-Stabilization, and After the First 2 Injections of SUBLOCADE5 A peak occurred around 24 hours, the first measurement post-injection, then slowly decreased to a plateau around 2 ng/mL for the first injection and 3 ng/mL for the second injection
Slide 14: Longer SUBLOCADE Treatment Shown to Improve Patient Outcomes
The longer the SUBLOCADE treatment duration, the higher the likelihood of continuous self-reported abstinence 12 months after treatment cessation % Abstinent subjects Length of SUBLOCADE treatment Source: Ling W, Nadipelli VR, Aldridge AP, Ronquest NA, Solem CT, Chilcoat H, Albright V, Johnson C, Le
Slide 15: New SUBLOCADE Label Benefits
New SUBLOCADE Label Benefits1 Label Updates Further Differentiate SUBLOCADE for Today’s Opioid Crisis Driven by the Proliferation of Synthetic Opioids START PATIENTS ON SUBLOCADE SOONER: Only monthly LAI to initiate on Day 1 with buprenorphine naive patients (no 7-day oral induction).1,2 2nd INJECTI
Slide 16: Strong Fundamentals Position SUBLOCADE for Growth
Broad Payor Access for SUBLOCADE High Intent to Prescribe 1 Active count of prescribing HCPs; excludes delisted and Specialty HCPs. 47% of HCPs expected to increase prescribing of SUBLOCADE in the next 18 months 2/3 of patients suitable for SUBLOCADE today (per HCPs) 90% of HCPs associate SUBLOCADE
Slide 17: Q3 2025 U.S. SUBLOCADE Performance
Q3 2025 U.S. SUBLOCADE Performance 17 1 Total number of dispenses (new and refill) within the quarter; Indivior analytics. 2 Rolling 12 mos. Estimated patients in treatment TTM SUBLOCADE Patients2 Solid SUBLOCADE Dispense Growth1 // +8% YoY +3% QoQ +5% YoY INVESTOR PRESENTATION | October 2025
Slide 18: Improving U.S. SUBLOCADE Commercial Execution to Generate Momentum
Improving U.S. SUBLOCADE Commercial Execution to Generate Momentum 18 OVERRIDING GOAL: Extend SUBLOCADE’s Position as No. 1 LAI Choice Field Force Execution: Improving field force messaging acumen and productivity Driving HCP awareness of label updates Payor Pull-Through: Leveraging broad access acr
Slide 19: Direct-To-Consumer Campaign: Move Forward in Recovery
Direct-To-Consumer Campaign: Move Forward in Recovery 19 Omnichannel patient activation initiative including: National television, digital, and social media In-office and point of care materials Newly designed patient website Committed to invest at sustained levels to drive awareness of SUBLOCADE an
Slide 20: Indivior
= iINDIVIOR
Slide 21: OUD Focused Pipeline
1 Treatment failure defined as either one of two criteria: (1) Urine Drug Screen positive for opioids, or fentanyl on 4 consecutive assessments while participants are on INDV-2000 or placebo alone, (2) Discontinued INDV-2000 or placebo prematurely. Trial Patients & Population Design Primary Endpoint
Slide 22: Indivior
SZ iNDIVIOR’ | as iN
Slide 23: Q3 2025 Business Highlights
SUBLOCADE Net Revenue Q3 2025 Business Highlights 1Adjusted EBITDA is a Non-GAAP Financial Measure with Net Income as the most directly comparable; Net Income/(loss) was $22m in Q3 2024 and $42m in Q3 2025; See Non-GAAP Financial Measures in the Appendix for reconciliation. Total Net Revenue Adjuste
Slide 24: Raising 2025 Financial Guidance
Raising 2025 Financial Guidance: Reflecting Stronger Top-Line Growth 24 1As of October 30, 2025, before exceptional items and assuming no material change in key FX rates vs. FY 2024 average rates. Financial data provided by Indivior in its press release on Form 8-K filed with the SEC on October 30,
Slide 25: "Go-Forward" Operating Model Established
Completed LSE delisting Restructured R&D and Medical Affairs organizations Discontinued sales and marketing support of OPVEE “Go-Forward” Operating Model Established 25 Expect at least $150m in Non-GAAP Operating Expense Savings in 20261,2 ~$60m Simplification Actions to Generate Savings 1Financial
Slide 26: Key Balance Sheet Items
Key Balance Sheet Items 1 Defined as Earnings Before Interest, Taxes, Deprecation and Amortization; See Non-GAAP Financial Measures in the Appendix for reconciliation; Net Income/(loss) of ($148m) in FY 2020, $205m in FY 2021, ($42m) in FY 2022, ($126m) in FY 2023 and $7m in FY 2024. 2 Based on the
Slide 27: Transition to U.S. Focused Business
Goals of Increasing U.S. Presence Transition to U.S. Focused Business 27 INVESTOR PRESENTATION | October 2025 Expand Indivior’s U.S. capital markets presence Align with Indivior’s focus on growing SUBLOCADE in the U.S. Simplify corporate governance and reduce complexity Increase potential U.S. equit
Slide 28: Appendix
_ INDIVIOR § Appendix
Slide 29: Q3 2025 Financial Highlights
Q3 2025 Financial Highlights 29 Columns and rows may not foot due to rounding. 1See non-GAAP Financial Measures in the Appendix for reconciliation. 2GAAP Selling and Marketing Expenses were $62m in Q3 2025 and $55m in Q3 2024, GAAP General and Administrative Expenses were $94m in Q3 2025 and $87m in
Slide 30: Financial Reconciliations: Gross Profit
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information 30 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 GAAP gross profit $230 $241 $702 $707 Adjustments within cost of sales Manufacturing transition 2 — 4 — Discontinuation of OPVEE
Slide 31: Financial Reconciliations: Operating Expenses
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information 31 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 GAAP operating expenses $187 $206 $521 $715 Share-based compensation 6 6 21 18 Corporate initiative transition1 35 — 41 — Discont
Slide 32: Financial Reconciliations: G&A Expenses
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information 32 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 GAAP general and administrative expenses $94 $87 $236 $250 Adjustments within G&A Share-based compensation 6 6 21 18 Corporate in
Slide 33: Financial Reconciliations: Selling and Marketing
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information 33 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 GAAP selling and marketing expenses $62 $55 $209 $188 Adjustments within S&M Corporate initiative transition1 6 — 6 — Discontinua
Slide 34: Financial Reconciliations: R&D Expenses
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information 34 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 GAAP research and development expenses $33 $22 $76 $76 Adjustments within R&D Corporate initiative transition1 13 — 13 — Less: Ad
Slide 35: Financial Reconciliations: Tax Expense
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information 35 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 GAAP tax expense (benefit) $(5) $8 $50 $(4) Tax on non-GAAP adjustments (19) (20) (26) (66) Tax settlement1 (1) — 32 — Other tax
Slide 36: Financial Reconciliations: Net Income
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information 36 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 GAAP net income (loss) $42 $22 $108 $(14) Adjustments in cost of sales 33 10 34 42 Adjustments in selling, general and administra
Slide 37: Financial Reconciliations: Adjusted EBITDA
Financial Reconciliations Reconciliation of GAAP to non-GAAP financial information 37 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net income (loss) $42 $22 $108 $(14) Interest (income) (6) (5) (16) (18) Interest expense 12 11 39 28 Income tax expense (benefit
Slide 38: FY 2020–2024 Non-GAAP Operating Expense Reconciliations
FY 2020–2024 Non-GAAP Operating Expense Reconciliations 38 INVESTOR PRESENTATION | October 2025 Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Reconciliation: IFRS to GAAP exceptionals within operating profit Q4 Reclassification US GAAP Operating Profit $73.209536594165002 $-,119.2966617134996 $33.69495403
Slide 39: FY 2020–2024 EBITDA Reconciliations
FY 2020–2024 EBTIDA Reconciliations 39 INVESTOR PRESENTATION | October 2025 Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Reconciliation: IFRS to GAAP exceptionals within operating profit Q4 Reclassification US GAAP Operating Profit $73.209536594165002 $-,119.2966617134996 $33.694954031548903 $44.12200566
Slide 40: FY 2024 & TTM Leverage Reconciliation
FY 2024 & TTM Leverage Reconciliation* 40 INVESTOR PRESENTATION | October 2025 *Columns may not foot due to rounding Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Reconciliation: IFRS to GAAP exceptionals within operating profit Q4 Reclassification US GAAP Operating Profit $73.209536594165002 $-,119.29666
Slide 41: SUBLOCADE Indication and Highlighted Safety Information
SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use (CIII) INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already bein